Week’s news headlines – apr. 30th 2015

Louis Vuitton loses battle over signature chequered pattern as EU ruling cancels two of the brand’s registered trademarks
French luxury label Louis Vuitton faced a ‘double blow’ over its use of its trademark chequerboard pattern after an EU court threw out its right to exclusively use its logo.

Celebrity-favourite Louis Vuitton had been fighting to protect its signature chequered squares since 2009

Saiba mais em: http://www.thisismoney.co.uk/money/markets/articl

 

 

 

Google takes aim at patent trolls with intellectual property marketplace

Firm wants to buy your patents to keep them out of the hands of trolls

Saiba mais em: http://www.theinquirer.net/inquirer/news/2406077/

 

 

 

The “Blurred Lines” of music and copyright: Part one

Possibly the highest-profile copyright case of the past 12 months centered on a trial between the creators of the catchy tune, “Blurred Lines”, and the Marvin Gaye estate over the song’s supposed similarities to the 1977 hit, “Got to Give it up”. The jury’s decision to award the Gaye family $7.4 million has been met with some consternation in both law and music circles, with Pharrell Williams reportedly telling the media that this verdict spells disaster for the creative industries.

Saiba mais em: http://blog.oup.com/2015/04/blurred-lines-copyright-part-one/

 

 

 

Intellectual property is high on the agenda for corporates, says SPAG report

A recently released report on the occasion of World IP Day(April 26th) titled ‘Benefit Sharing In A Globalized India’ by Strategic Partners Group (SPAG), a leading research and advocacy firm shows that Indian corporate leaders favors the need for a sustainable intellectual property (IP) framework in India.

Saiba mais em: http://businesstoday.intoday.in/story/intellect

 

 

 

Federal Circuit will rehear “disparaging marks” trademark case about The Slants — and the Redskins case may be affected

Federal trademark law denies certain protections to trademarks that “may disparage … persons, living or dead, institutions, beliefs, or national symbols, or bring them into contempt, or disrepute.” Does that exclusion violate the First Amendment? The Federal Circuit just agreed to rehear that question en banc, in the case involving the Asian-American band “The Slants” (which I discussed here). And the decision in the case may well affect the Redskins controversy, which is now pending.

Saiba mais em: http://www.washingtonpost.com/news

 

 

 

US software copyright registration is game changer

Global software leaders, Including Oracle, Sony, Adobe, Microsoft, SAP, Apple, and Amazon recognize the importance of US software copyrights and have registered thousands. Every Israeli software company should also protect their software with registered US copyrights.

Saiba mais em: http://www.globes.co.il/en/article-us

Read more

New rules, new oportunities…

2015 began with the publication of new rules in healthcare area that will contribute to the emergence of opportunities for industries in the sector and in the country as a whole.

 

The enactment of Law No. 13,097, on January 19th, 2015, has brought more flexibility to ANVISA’s actions, so that these actions are directed to situations of greater impact on society, ultimately allowing the development of the healthcare sector, as for example, in cases of clinical trials. Another advantage brought by this new law to the healthcare industries is related to the validity term of healthcare products’ registration under ANVISA’s surveillance. In fact, the referred law makes it possible to extend the validity term from 5 to 10 years, considering the product’s nature and the sanitary risks involved in its use. Furthermore, Law No. 13,097, establishes that the industries in the sector are exempted from payment of renewal fees.

 

Finally, for the purposes of supervision and monitoring of products subject to Health Surveillance system, the referred law also foresees the use of sanitary inspection reports by agencies or international institutions accredited by ANVISA.

 

Furthermore, ANVISA published Resolution RDC No. 09, on February 20, 2015, establishing new rules for the development of clinical trial of medicinal product in Brazil. This resolution defines the maximum period of 30 days for ANVISA to assess the Clinical Development of the Medicinal Product Report (DDCM) prepared by the company that either owns the drug or by the clinical agency doing the testing. Where ANVISA does not manifest in time, the clinical trial can be conducted, as long as it is approved on the ethical aspects of the research. However, regarding experimental drugs, in order to be allowed to proceed to Phase I and Phase II, as well for clinical development of biological products, the previous approval of ANVISA is still necessary. Clinical researches in the examination phase III, to be held simultaneously in different countries, will also benefit from this new rule.

 

The new rule also provides a type of approval that concentrates all phases of clinical studies into one single analysis, in order to harmonize national legislation on the subject with other international regulatory bodies.

language: EN-US’>

 

The new rule also provides a type of approval that concentrates all phases of clinical studies into one single analysis, in order to harmonize national legislation on the subject with other international regulatory bodies.

 

 

For more details please feel free to contact us:

diblasi@diblasi.com.br

Read more

Our Offices

developed by
Pedro.am